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Abstract
Background: During 2007 and 2008 it is likely that millions of patients in the US received heparin contaminated (CH) with
oversulfated chondroitin sulfate, which was associated with anaphylactoid reactions. We tested the hypothesis that CH was
associated with serious morbidity, mortality, intensive care unit (ICU) stay and heparin-induced thrombocytopenia following
adult cardiac surgery.
Methods and Findings:We conducted a single center, retrospective, propensity-matched cohort study during the period of
CH and the equivalent time frame in the three preceding or the two following years. Perioperative data were obtained from
the institutional record of the Society of Thoracic Surgeons National Database, for which the data collection is prospective,
standardized and performed by independent investigators. After matching, logistic regression was performed to evaluate
the independent effect of CH on the composite adverse outcome (myocardial infarction, stroke, pneumonia, dialysis, cardiac
arrest) and on mortality. Cox regression was used to determine the association between CH and ICU length of stay. The 1:5
matched groups included 220 patients potentially exposed to CH and 918 controls. There were more adverse outcomes in
the exposed cohort (20.9% versus 12.0%; difference = 8.9%; 95% CI 3.6% to 15.1%, P,0.001) with an odds ratio for CH of 2.0
(95% CI, 1.4 to 3.0, P,0.001). In the exposed group there was a non-significant increase in mortality (5.9% versus 3.5%,
difference = 2.4%; 95% CI, 20.4 to 3.5%, P = 0.1), the median ICU stay was longer by 14.1 hours (interquartile range 226.6 to
79.8, S = 3299, P = 0.0004) with an estimated hazard ratio for CH of 1.2 (95% CI, 1.0 to 1.4, P = 0.04). There was no difference
in nadir platelet counts between cohorts.
Conclusions: The results from this single center study suggest the possibility that contaminated heparin might have
contributed to serious morbidity following cardiac surgery.
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Introduction
In March 2008, the Federal Drug Administration (FDA)
announced that heparin from one of the major manufacturers
had been contaminated with oversulfated chondroitin sulfate
(OSCS). Suspicion for contamination arose because several
anaphylactoid reactions to heparin were reported, whereas
heparin, one of the most commonly administered hospital
medications, is rarely associated with such reactions. The
anaphylactoid reactions were most likely to have been caused by
activation of the kinin-kallikrein system leading to production of
the vasodilator bradykinin, and to stimulation of the alternative
complement pathway leading to synthesis of the potent anaphy-
lotoxins C3a and C5a [1–3].
When contamination was suspected, the manufacturer with-
drew its heparin. However, during the period that OSCS
contaminated heparin was in circulation, the FDA estimated that
up to 50% of the heparin in the US was from the manufacturer of
contaminated heparin [2]. Patients undergoing cardiac surgical
procedures typically receive large bolus doses (300 to 400 units/kg)
of heparin in order to achieve intense anticoagulation for
cardiopulmonary bypass. It is probable that many of the most
profound anaphylactoid reactions would have occurred in this
patient population. It is currently unknown specifically whether
patient outcomes from cardiac surgery were worse during the
period of OSCS contamination. Also it is generally unknown
whether appropriately managed anaphylactoid reactions are
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associated with increased morbidity and mortality beyond the
acute episode. OSCS contaminated heparin has been hypothe-
sized to increase the incidence of heparin-induced thrombocyto-
penia [4,5], which occurs relatively frequently in cardiac surgery
patients [6]. Interestingly, exogenous bradykinin might have a
cardioprotective role in cardiac surgery by attenuating myocardial
injury and through anti-inflammatory actions [7]. It is thus also
important to consider that OSCS heparin, through production of
bradykinin, might have improved outcomes after cardiac surgery.
We therefore conducted a single center propensity-matched
study including adult cardiac surgery patients to determine
whether during the period of OSCS heparin contamination there
were differences in morbidity, mortality, intensive care unit stay
(ICU), or heparin-induced thrombocytopenia following cardiac
surgery.
Methods
Study Design
This was a retrospective cohort study involving adult patients
undergoing cardiac surgery at Barnes-Jewish Hospital in St. Louis,
Missouri. The Washington University Human Research Protec-
tion Office approved the study and waived the requirement for
informed consent. The STROBE checklist for observational
studies was used to guide the methods of this study and to
structure this manuscript [8].
The investigation was designed to compare surgical patients
during the period of heparin contamination (potentially exposed
group) to patients who had their surgery during the equivalent
time frame in the three preceding or the two subsequent years
(control group). The time period inclusion criterion was to limit
the possibility of seasonal disparities in patient outcomes biasing
the results [9]. The first reports about serious adverse events or
deaths potentially caused by OSCS were submitted in November
2007, and the manufacturer recalled 9 lots of multi-dose heparin
vials on January 17th, 2008. The remaining multi- and single-dose
vials of heparin were recalled on February 28th, 2008. Based on
pharmacy invoices for this time period, all multi-dose vials of
heparin received by Barnes-Jewish Hospital were on the recall list.
Typically, heparin for cardiac surgery is administered from these
multi-dose vials, but the exact lot number of heparin for each
patient is not recorded. Therefore adult cardiac surgery patients at
Barnes-Jewish Hospital potentially received contaminated heparin
from November 2007 to February 2008.
Perioperative data were obtained from the institutional record
of the Society of Thoracic Surgeons National Database, for which
the data collection is prospective, standardized and performed by
independent investigators [10]. Patients older than eighteen
undergoing open cardiac surgical procedures requiring heparin
anticoagulation between November 1st and February 28th during
the years 2004 to 2010 were included. Patients with missing
information regarding demographics or perioperative variables
that were used for matching or regression analysis were excluded.
The primary outcome was a composite postoperative morbidity
outcome including myocardial infarction, stroke, pneumonia,
renal failure, and cardiac arrest during each patient’s hospital
stay as well as in-hospital mortality. As secondary outcomes we
analyzed Intensive Care Unit length of stay and the lowest
recorded platelet count during the first ten postoperative days to
compare severity of thrombocytopenia. Except for platelet count
these outcomes are defined in the Society of Thoracic Surgery
database [11]. A subgroup analysis for patients taking angiotensin-
converting-enzyme-inhibitors or angiotensin-receptor-blocker was
planned, as the angiotensin-converting-enzyme-inhibitors increase
bradykinin concentrations and could therefore modify the effects
of OSCS contaminated heparin [12]. But there is no distinction
between these medications in the Society of Thoracic Surgery
database.
Statistical Analysis
The differences in patient characteristics, co-morbidities and
details of the scheduled surgery between the potentially exposed
and the control group were evaluated with a student’s t-test and
chi-square test as deemed appropriate. Normality of continuous
variables was verified with one-sided Kolmogorov-Smirnov tests
before parametric statistics were applied. To further assess the
potential imbalance between the cohorts, the standardized
differences in means for each of the 24 variables was calculated
Table 1. Summary Statistics of Unadjusted Patient Outcome Before and After PS Matching during Heparin Contamination.
Before PS Matching After PS Matching
Control Exposed Control Exposed
(n =1197) (n =220) (n=918) (n=220)
Outcome n(%) or M(IQR) n(%) or M(IQR) P n(%) or M(IQR) n(%) or M(IQR) P
Composite Outcome* 172 (14.4%) 46 (20.9%) 0.01 110 (12.0%) 46 (20.9%) ,0.001
- MI 8 (0.7%) 4 (1.8%) 0.09 8 (0.9%) 4 (1.8%) 0.20
- Stroke 33 (2.8%) 9 (4.1%) 0.28 20 (2.2%) 9 (4.1%) 0.11
- Pneumonia 120 (10.0%) 33 (15.0%) 0.03 76 (8.3%) 33 (15.0%) 0.003
- Dialysis 33 (2.8%) 8 (3.6%) 0.47 23 (2.5%) 8 (3.6%) 0.35
- Cardiac Arrest 27 (2.3%) 6 (2.7%) 0.67 17 (1.9%) 6 (2.7%) 0.43
In-Hospital Mortality 51 (4.3%) 13 (5.9%) 0.29 32 (3.5%) 13 (5.9%) 0.10
ICU-LOS in hours 55.0 (27–120) 65.1 (28–134) 0.32 51.0 (27–103) 65.1 (28–134) ,0.001
Platelet Count6109/L 101.0 (75–130) 100.0 (74–134) 0.73 103.9 (76–136) 100.0 (74–134) 0.67
PS indicates propensity score; n, number of patients; %, number of patients in percent of total per group; M, median; IQR, interquartile range; MI, myocardial infarction;
ICU LOS, length of stay on the intensive care unit.
*Composite outcome is any postoperative myocardial infarction, stroke, pneumonia, renal failure with dialysis or cardiac arrest during hospitalization.
doi:10.1371/journal.pone.0106096.t001
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(Table S1). Due to the imbalances, propensity score matching was
done with up to five control patients for each potentially exposed
case based on characteristics, co-morbid covariates and surgical
details (Table S1). The nearest neighbor matching without
replacement was used with a caliper of 0.2 standard deviations
of the logit of a patient’s predicted propensity score, because it
resulted in the overall best balance and the smallest reduction in
number of potentially exposed patients. To account for the fact
that some potentially exposed cases could just be matched to one
control, weights were generated to correct for this disproportion.
Every potentially exposed patient received a weight of one and the
weights for the matched control units were calculated by nexposedi/
Table 2. Logistic Regression Model of Composite Outcome* during Heparin Contamination.
Covariates Levels Coefficient (b) SE t-Value OR (95% CI) P
CH-Exposure 0.70 0.20 3.42 2.0 (1.4–3.0) ,0.001
Age in years 18–44 reference reference reference reference
45–74 0.37 0.30 1.22 1.5 (0.8–2.6) 0.22
$75 0.88 0.34 2.59 2.4 (1.2–4.7) ,0.01
Race 0.14 0.30 0.48 1.2 (0.6–2.1) 0.63
Comorbidities # 0 reference reference reference reference
1–4 0.61 0.49 1.26 1.8 (0.7–4.8) 0.21
$5 1.07 0.53 2.00 2.9 (1.0–8.3) 0.045
LVEF $55% reference reference reference reference
40–54% 0.55 0.23 2.41 1.7 (1.1–2.7) 0.016
,40% 0.94 0.23 4.17 2.6 (1.7–4.0) ,0.001
CPB in minutes 0 reference reference reference reference
1–179 0.14 0.33 0.44 1.2 (0.6–2.2) 0.66
$180 1.04 0.37 2.84 2.8 (1.4–5.9) 0.005
TXA 20.21 0.20 21.08 0.8 (0.6–1.2) 0.28
Surgeon 20.52 0.29 21.81 0.6 (0.3–1.0) 0.07
SE indicates standard error; OR, odds ratio; CI, confidence interval; CH, contaminated heparin; #, number of comorbidities; LVEF, left ventricular ejection fraction; CPB,
cardiopulmonary bypass time; TXA, tranexamic acid. Overall fit: 2 Log likelihood ratio = 65.9, P,0.0001; Wald F = 5.8 on 12 and 906 degrees of freedom, P,0.0001;
Hosmer-Lemeshow: X2 = 4.9, Degrees of freedom=8, P = 0.87.
*Composite outcome is any postoperative myocardial infarction, stroke, pneumonia, dialysis or cardiac arrest.
doi:10.1371/journal.pone.0106096.t002
Table 3. Proportional Hazards Model of ICU-LOS during Heparin Contamination.
Covariates Levels Coefficient (b) SE z-Value HR (95% CI) P
CH-Exposure 0.17 0.08 2.08 1.2 (1.0–1.4) 0.038
Age in years 18–44 reference reference reference reference
45–74 0.35 0.09 3.69 1.4 (1.2–1.7) ,0.001
$75 0.66 0.11 5.74 1.9 (1.5–2.4) ,0.0001
Race 0.08 0.10 0.81 1.1 (0.9–1.3) 0.42
Comorbidities # 0 reference reference reference reference
1–4 0.17 0.13 1.30 1.2 (0.9–1.5) 0.19
$5 0.55 0.15 3.75 1.7 (1.3–2.3) ,0.001
LVEF $55% reference reference reference reference
40–54% 0.21 0.08 2.43 1.2 (1.0–1.5) 0.015
,40% 0.45 0.08 5.62 1.6 (1.3–1.8) ,0.0001
CPB in minutes 0 reference reference reference reference
1–179 0.19 0.12 1.63 1.2 (1.0–1.5) 0.10
$180 0.59 0.14 4.13 1.8 (1.4–2.4) ,0.0001
TXA 0.11 0.07 1.64 1.1 (1.0–1.3) 0.10
Surgeon 20.38 0.10 23.93 0.7 (0.6–0.8) ,0.0001
ICU-LOS indicates length of stay on the intensive care unit; SE, standard error; HR, hazard ratio; CI, confidence interval; CH, contaminated heparin; LVEF, left ventricular
ejection fraction; CPB, cardiopulmonary bypass time; TXA, tranexamic acid.
doi:10.1371/journal.pone.0106096.t003
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ncontroli, where nexposedi and ncontroli were the number of potentially
exposed and control units in stratum i. The control group weights
were scaled then to sum to the number of uniquely matched
control units. Following propensity score matching the balance of
the matched potentially exposed and control groups was evaluated
by calculating variance ratios, absolute values of the standardized
differences in means as well as Hotelling’s test. Furthermore, a
weighted t-tests or chi-square test were performed as appropriate
[13–17].
Unadjusted analyses were initially conducted for all outcomes.
To depict the influence of the propensity score matching on the
differences in outcomes, a chi-square or Wilcoxon Rank-Sum test
was used before, and a weighted McNemar’s test or Wilcoxon
Signed Rank test after matching as indicated. For the subgroup
analyses of angiotensin-converting-enzyme inhibitor or angioten-
sin-receptor blocker versus events of composite outcome a
weighted chi-square test was applied.
Adjusted analyses comprised conditional multivariable logistic
regression using data from the matched patient cohort to evaluate
the independent effect of contaminated heparin on the composite
outcome and on mortality. Proportional hazards Cox regression
was used to determine the association between contaminated
heparin and ICU length of stay. We checked proportionality of
hazards by testing for non-zero slopes in a generalized linear
regression of the scaled Schoenfeld residuals on functions of time,
and additionally graphically by eye. Covariates were defined a-
priori by their clinical significance in the Euroscore II [18]. The
number of covariates per logistic regression model was restricted to
at least 10 events per covariate to decrease the likelihood of
overfitting. Covariates included heparin – uncontaminated or
potentially contaminated, age (categorical with 3 levels), race
(dichotomous), number of co-morbidities (categorical with 3
levels), left ventricular ejection fraction (categorical with 3 levels),
cardiopulmonary bypass time (categorical with 3 levels), Tranexa-
mic acid (dichotomous), and surgeon experience (dichotomous:
Junior (instructor or assistant professor) versus senior (associate or
full professor) surgeon). Only heparin, co-morbidities, left ventric-
ular ejection fraction, and cardiopulmonary bypass time were used
as covariates for the mortality logistic regression model. All
variables were entered with the main factor of interest, heparin
exposure, in a single step of the model. Goodness of fit for the
logistic regression was assessed with the log likelihood ratio, Wald
and Hosmer-Lemeshow tests. For the proportional hazards Cox
regression the proportionality assumption was checked. A p-value
,0.05 was considered significant in all applied tests. SPSS Version
21 (IBM, Armonk, New York) was used for data handling, and R
(The R Foundation for Statistical Computing, Version 2.15.3) with
the packages MatchIt [16] and Survey [19] was used for statistical
analyses. At the request of the handling editor, using the raw data,
the statistical analyses were repeated by an independent statistician
(NL). The approaches used for these independent analyses were
similar to those used in the initial analyses.
Results
Of the 1417 patients meeting the inclusion criteria there were
220 during the period of contaminated heparin (2007 to 2008) and
1197 during the corresponding period in the three preceding and
two subsequent years. Seven patients were excluded from the
initial database (n = 1424) due to missing covariate information
(0.49%). The two groups differed significantly in certain charac-
teristics and co-morbidities (Table S1). This resulted in a
significantly different overall propensity score of 0.15 in the
control group and 0.19 in the potentially exposed group (P,
0.001). Following propensity score matching there were no
significant differences between the groups with standardized mean
difference not exceeding 0.25, no variance ratio outside the range
of 0.5–2, and a non-significant Hotelling’s test (P = 0.985). Of the
control patients, 279 were not suitable for matching. Interestingly,
correction of the imbalances through matching did not substan-
tially alter the findings for the composite postoperative complica-
tion outcome (Table 1).
After propensity score matching, there were significantly more
adverse outcomes in the potentially exposed group (20.9% versus
12.0%, difference = 8.9%; 95% CI 3.6 to 15.1%, P,0.001), and a
statistically non-significant difference in patient in-hospital mor-
tality with 5.9% in the potentially contaminated versus 3.5% in the
control group (difference = 2.4%; 95% CI 20.4 to 3.0%, P= 0.1).
The median ICU length of stay was significantly longer by 14.1
hours (interquartile range 226.6 to 79.8 hours, S = 3299,
P= 0.0004). The median lowest platelet counts were similar with
100.06109/L in the potentially exposed and 100.86109/L in the
control group (interquartile range 230.0 to 33.5, S = 385,
P= 0.67).
After adjusting for age, race, number of co-morbidities, left
ventricular ejection fraction, cardiopulmonary bypass time,
administration of Tranexamic acid, and experience of the surgeon,
contaminated heparin proved to be a significant factor for the
composite postoperative complication outcome with an odds ratio
of 2.0 (95% CI, 1.4 to 3.0, P,0.001) (Table 2). Contaminated
heparin did not prove to be a significant predictor for in-hospital
mortality (Odds ratio 1.9, 95% CI 0.9 to 3.5, P= 0.11, other odds
ratios not shown in detail), but it revealed being significantly
associated with a longer stay on the ICU postoperatively (Hazard
ratio 1.2, 95% CI 1.0 to 1.4, P= 0.038) (Table 3).
The subgroup analysis for patients being on an angiotensin-
converting-enzyme inhibitor or an angiotensin-receptor blocker
revealed a potentially protective effect with respect to the
composite outcome within the control (9.5% versus 14.5%,
difference = 5.0%, 95% CI 0.8 to 9.2%, P=0.02), but not within
the exposed group (Table 4). The largest difference was seen
between patients being on an angiotensin-converting-enzyme
Table 4. Subgroup Analysis of ACEI and ARB: Regular versus Potentially Contaminated Heparin.
Events*/Control Events*/Exposed P
On ACEI/ARB 38/402 (9.5%) 18/103 (17.5%) 0.021
No ACEI/ARB 75/516 (14.5%) 28/117 (23.9%) 0.013
P 0.02 0.24
ACEI indicates angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker.
*Events of composite outcome.
doi:10.1371/journal.pone.0106096.t004
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inhibitor or an angiotensin-receptor blocker receiving regular
heparin in comparison to patients receiving contaminated heparin
and not taking an angiotensin-converting-enzyme inhibitor or an
angiotensin-receptor blocker (9.5% and 23.9% respectively,
difference = 14.4%, 95% CI 6.9 to 23.3%, P= 0.013).
Summary of findings from independently repeated
statistical analysis
In general the findings of the independently repeated statistical
analysis were similar to those found initially. Most notably, for the
composite postoperative complication outcome using logistic
regression, potential exposure to contaminated heparin had a
statistically significant effect with p value = 0.0025 and odds
ratio = 1.897. This analysis was repeated for other matched
samples, and the p value was persistently below 0.05. For
mortality, potential exposure to contaminated heparin showed a
statistically insignificant effect with p value = 0.0772 and odds
ratio = 1.908. In contrast to the initial analysis, potential exposure
to contaminated heparin was associated with a non-significant
(P = 0.065) risk for increased intensive care unit stay.
Discussion
This single center study found that OSCS heparin contamina-
tion might have been associated with increased morbidity and
length of ICU stay following cardiac surgery. This is the first study
to show that OSCS contamination might have had a broad
negative impact rather than sporadically and often transiently
causing adverse events related to anaphylactoid reactions.
However, contrary to previous suggestions, this study found no
evidence that OSCS heparin worsened thrombocytopenia, or by
implication might have promoted heparin-induced thrombocyto-
penia. This trial also did not find that OSCS heparin, through
bradykinin production, improved outcomes following cardiac
surgery.
The credibility of the main findings is supported by several
factors. First, the results were similar with and without propensity
score matching. Second, the estimated incidence for each of the
individual complications in the composite outcome was higher in
the patients who potentially received OSCS contaminated
heparin. Third, the results are mechanistically plausible, as
hypotension-induced organ dysfunction and bradykinin-triggered
inflammation with vascular permeability seen with angioedema
might have driven the adverse outcomes [20]. If OSCS
contaminated heparin was associated with adverse outcomes,
mechanisms other than bradykinin production might have been
involved as patients in the control group who were taking an
angiotensin-converting-enzyme inhibitor (also associated with
increased bradykinin [11]) had fewer complications. The protec-
tive effect of angiotensin-converting-enzyme inhibitors could be
attributable to blocking the increased expression of pro-inflam-
matory factors triggered by angiotensin II and by reducing the
stimulation of superoxide formation [21,22].
This epidemiological study provides indirect evidence that
anaphylactoid reactions are probably associated with worse
outcomes, even if the acute episode is managed appropriately.
This inference is based on four key assumptions. The first is that
OSCS heparin was actually associated with increased morbidity
and the results in this study were not just spurious. The second is
that the anaphylactoid reactions to OSCS heparin were managed
appropriately when they occurred in the operating room. The
third assumption is that the adverse outcomes were attributable to
anaphylactoid reactions rather than to some other consequence of
OSCS. Finally, it is assumed that patients included in this study
actually received OSCS contaminated heparin.
This study had important limitations. As this was a non-
randomized, retrospective, observational study, there might have
been uncontrollable, unknown or hidden confounding factors
[17,23]. We attempted to address this through propensity score
matching followed by multivariable regression analysis. However,
important data known to impact outcomes after cardiac surgery,
such as blood component transfusions [24], were incomplete, and
could not be included in the analyses. This was a single center
study with relatively low numbers; as such the findings are
potentially fragile and imprecise. Finally, it is unknown which
specific patients received contaminated heparin and detailed
hemodynamic data from the operating room were not available.
In conclusion, we compared the outcomes of patients under-
going adult cardiac surgery who potentially received OSCS
contaminated heparin and those who received uncontaminated
heparin. Exposure to contaminated heparin appears to have been
associated with increased risk of postoperative complications and
longer ICU stay. This result must be regarded only as hypothesis-
generating as it was an observational study from a single center in
the United States. In order to clarify whether or not there was an
increase in morbidity and perhaps mortality for patients under-
going heart surgery during the period that OSCS heparin was
available, we have approached the Society for Thoracic Surgeons
national organization and have requested access to national STS
data so that we can repeat our analysis on a much larger scale,
which should provide sufficient patient numbers and a broadly
representative cohort in order to answer the hypothesis with
confidence and precision.
Supporting Information
Table S1 Characteristics of all Covariates Before and
After Propensity Score Matching during Heparin Con-
tamination. PS indicates propensity score; n, number of
patients; %, number of patients in percent of total per group; m,
mean; SD, standard deviation; d, standardized mean difference;
BMI, body mass index; ACEI, angiotensin-converting-enzyme
inhibitor; ARB, angiotensin-receptor blocker; CVD, cerebrovas-
cular disease; PAH, pulmonary hypertension; NIDDM, non–
insulin-dependent diabetes mellitus; IDDM, insulin-dependent
diabetes mellitus; MI, myocardial infarction; CAD, coronary
artery disease; LVEF, left ventricular ejection fraction; IABP,
intra-aortic balloon pump; CABG, coronary artery bypass graft.
*Valvular insufficiency or stenosis of moderate or severe Grade.
{Surgery performed by an Instructor or Assistant Professor in
Cardiac Surgery. {Previous Cardiovascular Intervention, either
Surgical or Non-surgical. 1Any cardiac operation involving a heart
valve with or without a concomitant coronary artery bypass graft.
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